In a similar study, Zhang et al. [113] analyzed the expression of serum miR-222-3p to determine its contribution to the early prediction of therapeutic response, clinical outcomes, and adverse events in HER2+ BC patients receiving NAT. Here, ERBB2 is linked to breast cancer.